Navigation Links
Hepatitis B Foundation awards UT School of Public Health professor
Date:1/8/2010

HOUSTON (Jan. 8, 2010) R. Palmer Beasley, M.D., Ashbel Smith Professor at The University of Texas School of Public Health, has been awarded the Hepatitis B Foundation's Distinguished Scientist Award 2010.

"The HBV vaccine, the first cancer vaccine, provides long-term protection against hepatitis B infection, which is responsible for a large proportion of liver cancer in the world. Ultimately, HBV can be eradicated," said Beasley. "This honor from the Hepatitis B Foundation provides another tool to encourage the world to use the vaccine vigorously."

For more than 18 years, Beasley served as dean of the UT School of Public Health. Beasley has pioneered work in perinatal hepatitis B virus transmission, which showed that mother-infant transmission was the most important factor in sustaining hepatitis B virus infection in Asia. He also did the definitive research that proved that hepatitis B causes primary liver cancer and led the global effort to convince the World Health Organization to establish the HBV vaccine as the first human cancer vaccine.

"Dr. Beasley's contributions to understanding the link between hepatitis B and liver cancer have saved thousands of lives. His work not only transformed our understanding of the cause of liver cancer, but then spearheaded the solution through vaccination," said Roberta B. Ness, M.D., dean of the UT School of Public Health. "We are certainly proud to call him one of our own."

This award is the highest scientific honor awarded by the foundation in recognition and appreciation for the research of hepatitis B.


'/>"/>

Contact: Jade Waddy
jade.waddy@uth.tmc.edu
713-500-3030
University of Texas Health Science Center at Houston
Source:Eurekalert

Page: 1

Related medicine news :

1. NVHR Offers Congressman Hank Johnson Support & Encouragement as He Battles Chronic Hepatitis C Virus
2. New Hepatitis C Treatment Shows Promise
3. NVHR: New Data Finding Fewer than 1 in 5 Hepatitis C Patients Receiving Antiviral Therapy is Wake-Up Call for Washington
4. Alarming trend -- antiviral therapy to treat hepatitis C is declining in the US
5. Lloyd Wright's Alternative Medicine Has One of its Hepatitis C Viral Inhibitors Given Boost as Scripps Study Peptides Effectiveness
6. NVHR: New JAMA Article Underscores Urgent Need for Congress to Act on Viral Hepatitis Detection, Management Funding
7. Lloyd Wright's Alternative Medicine Marketing Only Blueberry Extract with 45% of Hepatitis C Inhibitor Proanthocyanidin
8. African Americans Fare Worse After Undergoing Liver Transplantation Due to Hepatitis C
9. Extending treatment after liver transplant may benefit patients with hepatitis C recurrence
10. Hepatitis B does not increase risk for pancreatic cancer
11. Brown & Toland Supports Fight Against Hepatitis B
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/23/2017)... ... August 23, 2017 , ... Based on ... safety and efficacy of HBOT in treating and helping to heal addictions and ... research showing the similarities of the wounds to the brain from traumatic brain ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... healthcare industry, made the 2017 Inc. 5000 with a three-year sales growth ... nation’s fastest-growing private companies and comprises the most comprehensive look at America’s independent ...
(Date:8/23/2017)... ... 2017 , ... MobilityWorks ®, the nation's largest retailer ... Inc. 500|5000, an exclusive ranking of America’s fastest-growing private companies. MobilityWorks (aka WMK) ... the twelfth year that the company has been included on the list. , ...
(Date:8/23/2017)... , ... August 23, 2017 , ... ... the American Academy of Orthopaedic Surgeons , points out that therapeutic modalities ... from pain or injury. According to the report, a wider scope of physical ...
(Date:8/22/2017)... ... August 22, 2017 , ... The old adage ... as simple as eating healthy foods. But this well-known piece of nutrition advice ... or breaking apart carbohydrates—depends not only on properties of the food but also ...
Breaking Medicine News(10 mins):
(Date:8/8/2017)... 2017   Second-quarter ... (GAAP) loss per share from continuing operations ... increased 16 percent to $110 million ... percent to $161 million ... continuing operations increased 8 percent to $0.93 ...
(Date:8/7/2017)... Aug. 7, 2017 Zimmer Biomet Holdings, Inc. (NYSE ... announced that its Board of Directors has approved the payment ... quarter of 2017. The ... or about October 27, 2017 to stockholders of record as ... declarations of dividends are subject to approval of the Board ...
(Date:8/7/2017)... Aug. 7, 2017  Diplomat Pharmacy, Inc. (NYSE: DPLO), the ... quarter ended June 30, 2017.  All comparisons, unless otherwise noted, ... Second Quarter 2017 Highlights include: ... $1,089 million, an increase of 3.5% Total ... Gross margin of 7.5% versus 7.6% ...
Breaking Medicine Technology: